Cascade Impactor Practice for a High Dose Dry Powder Inhaler at 90 L/min: NGI Versus Modified 6-Stage and 8-Stage ACI

2009 ◽  
Vol 98 (3) ◽  
pp. 1028-1039 ◽  
Author(s):  
Akihiko Kamiya ◽  
Masahiro Sakagami ◽  
Peter R. Byron
Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 189
Author(s):  
Zhanying Zheng ◽  
Sharon Shui Yee Leung ◽  
Raghvendra Gupta

Dry powder inhaler (DPI) is a device used to deliver a drug in dry powder form to the lungs. A wide range of DPI products is currently available, with the choice of DPI device largely depending on the dose, dosing frequency and powder properties of formulations. Computational fluid dynamics (CFD), together with various particle motion modelling tools, such as discrete particle methods (DPM) and discrete element methods (DEM), have been increasingly used to optimise DPI design by revealing the details of flow patterns, particle trajectories, de-agglomerations and depositions within the device and the delivery paths. This review article focuses on the development of the modelling methodologies of flow and particle behaviours in DPI devices and their applications to device design in several emerging fields. Various modelling methods, including the most recent multi-scale approaches, are covered and the latest simulation studies of different devices are summarised and critically assessed. The potential and effectiveness of the modelling tools in optimising designs of emerging DPI devices are specifically discussed, such as those with the features of high-dose, pediatric patient compatibility and independency of patients’ inhalation manoeuvres. Lastly, we summarise the challenges that remain to be addressed in DPI-related fluid and particle modelling and provide our thoughts on future research direction in this field.


Pharmaceutics ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 24 ◽  
Author(s):  
Imco Sibum ◽  
Paul Hagedoorn ◽  
Markus P. G. Kluitman ◽  
Martijn Kloezen ◽  
Henderik W. Frijlink ◽  
...  

Tuberculosis is the leading cause of death from a single infectious pathogen worldwide. Lately, the targeted delivery of antibiotics to the lungs via inhalation has received increasing interest. In a previous article, we reported on the development of a spray-dried dry powder isoniazid formulation containing an L-leucine coating. It dispersed well but had poor physical stability. In this study, we aimed to improve the stability by improving the leucine coating. To this end, we optimized the spray-drying conditions, the excipient content, and the excipient itself. Using L-leucine, the tested excipient contents (up to 5%) did not result in a stable powder. Contrary to L-leucine, the stability attained with trileucine was satisfactory. Even when exposed to 75% relative humidity, the formulation was stable for at least three months. The optimal formulation contained 3% trileucine w/w. This formulation resulted in a maximum fine particle dose of 58.00 ± 2.56 mg when a nominal dose of 80 mg was dispersed from the Cyclops® dry powder inhaler. The improved moisture protection and dispersibility obtained with trileucine are explained by its amorphous nature and a higher surface enrichment during drying. Dispersion efficiency of the device decreases at higher nominal doses.


2019 ◽  
Vol 108 (2) ◽  
pp. 949-959
Author(s):  
Stewart Yeung ◽  
Daniela Traini ◽  
Alan Tweedie ◽  
David Lewis ◽  
Tanya Church ◽  
...  

2009 ◽  
Vol 98 (8) ◽  
pp. 2770-2783 ◽  
Author(s):  
Philippe Begat ◽  
David A.V Morton ◽  
Jagdeep Shur ◽  
Paul Kippax ◽  
John N Staniforth ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document